The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

“After working with my dermatologist, she recommended I start Dupixent, a treatment for people ages 6 months and older with uncontrolled moderate-to-severe eczema.” Dupixent, known clinically ...

AT LEAST $50,000 IN DAMAGES. ALSO, THE OWNER OF A MED SPA HAS BEEN ARRESTED, ACCUSED OF IMPORTING COUNTERFEIT BOTOX AND USING IT FOR THOUSANDS OF INJECTIONS. WE SAW AUTHORITIES. YOU SEE THEM RIGHT ...

Patricia Lines died less than a week after getting a Vitamin B12 injection into her shoulder, a coroner's court has heard. The 77-year-old was taken to hospital where the infection worsened due ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023 Third quarter 2024 Dupixent ® global net sales (recorded by Sanofi) increased 23% to $3.82 billion versus ...

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...